CALGARY, Alberta, September 22, 2003 – Dr. Brad Thompson, Chairman, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview to analysts, portfolio managers, investment bankers and other financial professionals at the 5th Annual UBS Warburg Global Life Sciences Conference. The conference will be held at The Plaza Hotel in New York City on September 22-25, 2003. Dr. Thompson will make his presentation on Thursday, Sept. 25, 2003 at 2:30 p.m. ET.
A live audio webcast of the presentation will be available on the UBS website http://www.ibb.ubs.com/ or on the company’s website at www.oncolyticsbiotech.com. It is recommended that listeners log on 15 minutes in advance of the presentation to register and download any necessary software.
An audio replay of the presentation will begin three hours after the presentation time and will be available until October 25, 2003 on the UBS website.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of REOLYSIN®, its proprietary formulation of the human reovirus, as a potential cancer therapeutic. Oncolytics’ researchers have demonstrated that the reovirus is able to selectively kill human cancer cells in vitro that are derived from many types of cancer, including breast, prostate, pancreatic and brain tumours, and have also demonstrated successful cancer treatment results in a number of animal models. Phase I clinical trial results have indicated that there were no toxicology-related issues with the administration of the reovirus, and that the reovirus demonstrated activity in tumours injected with REOLYSIN®.
The webcast time is subject to change. This release and the presentation related thereto contain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company’s control and which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements.